
    
      This study is designed to investigate the potential therapeutic effects and safety of oral
      ALK4290 administered 800 mg daily over a 6-week dosing period as measured by Best Corrected
      Visual Acuity (BCVA) in subjects with refractory wAMD (i.e., following monthly intravitreal
      [IVT] anti-VEGF therapy for at least 3 months in the study eye).
    
  